alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferaseGenealiases: GNT-V · GNT-VA · MGAT5A · glcNAc-T V
Q-omics provides the consensus-scored MGAT5 profile across patient tissues and cancer cell-line models. MGAT5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MGAT5 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, MGAT5 RNA expression shows 20,763 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, COAD, and ACC as cancer lineages where MGAT5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MGAT5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MGAT5 survival associations across molecular data types. MGAT5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MGAT5 RNA expression–survival associations across cancer types. High MGAT5 expression shows unfavorable associations in MESO, ACC, UVM and KICH, but favorable associations in KIRC and STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MGAT5 RNA expression.
This table summarizes MGAT5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MGAT5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MGAT5 shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, LIHC, HNSC and STAD. The COAD box plot shows higher MGAT5 RNA expression in tumor versus normal tissue (log2 FC = +1.415, t-test p < 0.001).
This table shows molecular features associated with MGAT5 in patient tissues and cancer cell lines. In patient samples, MGAT5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MGAT5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
